The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections-Reference-Cited by-同舟云学术

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections

Published:2022-07-19 Issue:7 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gebremariam Teclegiorgis¹,Gu Yiyou¹,Alkhazraji Sondus¹,Youssef Eman¹²,Shaw Karen Joy³,Ibrahim Ashraf S.¹⁴^ORCID

Affiliation:

1. The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA

2. Beni-Suef University, Beni-Suef, Egypt

3. Hearts Consulting Group, LLC, Poway, California, USA

4. David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Abstract

Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broad-spectrum activity in animal models of infections.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Amplyx

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00380-22

Reference42 articles.

1. The anti-Aspergillusdrug pipeline: Is the glass half full or empty?: Table 1.

2. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management